KLASSEN PRESTON (President & Head of R & D) purchased 33.3% of their position (12K shares) of REGULUS THERAPEUTICS INC. on the open market
Open‑market purchase worth $95.9K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 6/4/2025ACC: 0000950170-25-081715
Officer· President & Head of R & D
Since Jun 2023
+12K
Net shares
Net buyer
$95.9K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
12K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+12K
Price / share
$7.99
Trade value
$95.85K
% of position
33.3%
6/3/2025
36.05K→48.05K
Total
Net shares
+12K
Net value
$95.85K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/3/2025 | P · Purchase | +12K | $7.99 | $95.85K | 33.3% | 36.05K | 48.05K |
| Total | +12K | $95.85K | ||||||
Derivative Transactions0
No derivative transactions reported